Furthermore, mice receiving sh-lincRNAp21 therapy had improved anemia status with significantly higher Hb levels, hematocrit (Hct) percentages and RBC numbers than those under the sh-luciferase treatment (Figure 6B, Hb, 8.8 ± 0.6 versus 10.6 ± 0.6 g/dL, p = 0.030; Hct, 36.5 ± 2.5 versus 45.9 ± 1.8%, p = 0.005; RBC, 6.6 ± 0.4 versus 8.0 ± 0.4 106/μL, p = 0.017). Here, GSTM1 is linked to anemia (phenotype).